Schizophrenia Clinical Trials in Hialeah, Florida

5 studies are recruiting for schizophrenia in Hialeah, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

    This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, Hialeah, Florida
    Locations
    19 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07105111 on ClinicalTrials.gov

  2. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    United Research Institute, Hialeah, Florida
    Locations
    64 in total
    Run by
    Intra-Cellular Therapies, Inc.

    See if you can join NCT06229210 on ClinicalTrials.gov

  3. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

    The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

    Stage
    Not phased
    Ages
    18 and older
    Site
    Galiz Research, Hialeah, Florida
    Locations
    55 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07379827 on ClinicalTrials.gov

  4. Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

    This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

    Stage
    Phase 1
    Ages
    10 to 17
    Site
    Bioxcel Clinical Research Site, Hialeah, Florida
    Locations
    5 in total
    Run by
    BioXcel Therapeutics Inc

    See if you can join NCT05025605 on ClinicalTrials.gov

  5. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

    Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Galiz Research Site, Hialeah, Florida
    Locations
    73 in total
    Run by
    Otsuka Pharmaceutical Development & Commercialization, Inc.

    See if you can join NCT06894212 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.